RIPK1 and RIPK3 - emerging targets in cancer?

  • Kerem Gurol Master Program in Pharmacology and Experimental Therapeutics, Tufts University, Sackler School of Graduate Biomedical Sciences, 136 Harrison Ave, Boston, MA 02111, USA
  • Suraj Shah Department of Developmental, Molecular and Chemical Biology, Tufts University, Sackler School of Graduate Biomedical Sciences, 136 Harrison Ave, Boston, MA 02111, USA
  • Alexei Degterev Department of Developmental, Molecular and Chemical Biology, Tufts University, Sackler School of Graduate Biomedical Sciences, 136 Harrison Ave, Boston, MA 02111, USA
DOI: 10.26781/2052-8426-2018-03

Abstract

RIPK1 and RIPK3 are homologous Ser/Thr kinases, which act in concert within the necrosome complexes to initiate a sub-type of regulated necrosis, termed necroptosis. Necroptosis has gradually emerged as a highly clinically relevant form of necrosis, which can be targeted therapeutically. Besides necroptosis, RIPK1 and RIPK3 have been implicated in other pathophysiologically-relevant responses, including regulation of apoptosis and inflammation. More recently, it became evident that RIPK1/RIPK3 pathways may be systematically altered in cancers. Status of these pathways may provide a prognostic value, and therapeutic modulation of RIPK1/RIPK3 signaling may represent a new strategy against various forms of human cancer.

Published
2018-03-15
How to Cite
GUROL, Kerem; SHAH, Suraj; DEGTEREV, Alexei. RIPK1 and RIPK3 - emerging targets in cancer?. Molecular and Cellular Therapies, [S.l.], v. 6, n. 1, mar. 2018. ISSN 2052-8426. Available at: <http://molcelltherapies.com/article/view/204>. Date accessed: 19 apr. 2018. doi: https://doi.org/10.26781/2052-8426-2018-03.